PRNewsWire
02 Oct 2026, 06:31 UTC · 11h ago
Verdict
Headline takes no side. We score LUNDB.CO +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Lundbeck's Phase III MASCOT trial of amlenetug in MSA enrolled 401 participants for a 72-week double-blind treatment period.
Newpress release dated Oct 02, 2026
So whatTop-line results are expected in Q3 2027, creating a binary catalyst for the stock in approximately 11 months.
More positive than 79% of claims this week
Lundbeck will present new Phase Ib data for Lu AF28996, an oral D1-like/D2-like dopamine receptor agonist for advanced Parkinson's disease.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Newpress release dated Oct 02, 2026
So whatThe 18-week trial results provide the first human safety/tolerability signal for this novel asset, impacting early-stage pipeline valuation.
More positive than 66% of claims this week
A US observational database study shows higher healthcare costs and resource utilization for MSA compared to Parkinson's disease.
Newpress release dated Oct 02, 2026
More positive than 44% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company is showcasing progress in its movement disorders pipeline and announcing Phase III trial enrollment for amlenetug.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
7h ago
—
No price for LUNDB.CO right now — the quote feed didn't answer.
LUNDB.CO chart →
